Blueprint Medicines Current Ratio 2014-2021 | BPMC

Current and historical current ratio for Blueprint Medicines (BPMC) from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Blueprint Medicines current ratio for the three months ending June 30, 2021 was 5.62.
Blueprint Medicines Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.70B $0.13B 5.62
2021-03-31 $0.94B $0.11B 8.34
2020-12-31 $0.93B $0.13B 7.09
2020-09-30 $0.84B $0.11B 7.64
2020-06-30 $0.57B $0.11B 5.41
2020-03-31 $0.71B $0.10B 7.17
2019-12-31 $0.52B $0.11B 4.85
2019-09-30 $0.51B $0.09B 5.46
2019-06-30 $0.61B $0.08B 7.52
2019-03-31 $0.43B $0.07B 6.59
2018-12-31 $0.50B $0.06B 8.29
2018-09-30 $0.57B $0.06B 10.05
2018-06-30 $0.62B $0.05B 12.36
2018-03-31 $0.62B $0.04B 15.39
2017-12-31 $0.69B $0.04B 15.98
2017-09-30 $0.40B $0.04B 11.28
2017-06-30 $0.43B $0.03B 13.07
2017-03-31 $0.21B $0.03B 8.31
2016-12-31 $0.22B $0.03B 7.73
2016-09-30 $0.16B $0.02B 6.54
2016-06-30 $0.18B $0.03B 6.42
2016-03-31 $0.20B $0.02B 8.31
2015-12-31 $0.17B $0.02B 9.14
2015-09-30 $0.19B $0.02B 9.78
2015-06-30 $0.20B $0.01B 13.94
2015-03-31 $0.05B $0.02B 3.57
2014-12-31 $0.05B $0.01B 7.14
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B $0.00B 0.78
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.992B $0.794B
Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76